Save up -80% on Vemurafenib
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Zelboraf
|$5,158||112 tablets/240 mg|
|Price with discount in nearest pharmacy. Price may vary.|
We offer free Vemurafenib coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Vemurafenib every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Vemurafenib volume of distribution
The estimation of the volume of distribution for Vemurafenib is 106 L.
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Vemurafenib
Vemurafenib is a BRAF enzyme inhibitor developed by Plexxikon and Genentech for the treatment of late-stage melanoma.[Wikipedia]The cobas 4800 BRAF B600 mutation test provided by Roche Molecular Systems is the diagnostic test to confirm eligibility for treatment. FDA approved on August 17, 2011 under the company Hoffmann La Roche.
Vemurafenib mechanism of action
Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase. It is especially potent against the BRAF V600E mutation. This mutation involves the substitution of glutamic acid for valine at codon 600. The BRAF oncogene, most of which have the V600E mutation, activates mitogen-activated kinase (MAPK) pathway which results in cell growth, proliferation, and metastasis. Vemurafenib blocks these downstream processes to inhibit tumour growth and eventually trigger apoptosis. Vemurafenib does not have antitumour effects against melanoma cell lines with the wild-type BRAF mutation.
Dosage forms of Vemurafenib
|Film-coated tablet||Oral use||240 mg|
|Tablet, film coated||oral||240 mg/1|
BRAF(V600E) Kinase Inhibitor RO5185426 PLX4032
Hoffmann La Roche Limited
Humans and other mammals
Indication of Vemurafenib
Treatment of unresectable or metastatic melanoma in patients with the BRAF-V600 mutation.
Toxicity of Vemurafenib
The most common AEs of all severity grades were rash (49%), arthralgia (39%), fatigue (34%), photosensitivity (31%), alopecia (26%) and nausea (19%). Forty-six percent of patients experienced grade 3 or 4 AEs, which were most commonly cutaneous SCC (12%), rash (5%), liver function abnormalities (5%), arthralgia (3%) and fatigue (3%).
RX24 Drugs Disclaimer: consult your healthcare provider before buying a Vemurafenib on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.